Fibromyalgia: cannabis research overview
Fibromyalgia involves more than pain. Fatigue, sleep and activity tolerance should also be assessed. Define practical goals and discuss with the team which existing measures should continue or be adjusted.
Research profile, not a treatment recommendation
Evidence
Cannabis studies in fibromyalgia are small and test different preparations. The 2023 review describes limited evidence; the updated 2025 AHRQ assessment also does not justify a universally recommended product profile. Possible changes in pain and quality of life must be read alongside adverse effects and study limitations. For each study, check who participated, what was compared and whether the measured difference matters in everyday life.
Mechanism of action
A mechanism described in a laboratory is not evidence of benefit in humans. Clinical outcomes for the specific condition and medicine matter. Receptor or terpene models do not predict individual treatment success.
Understanding cannabinoid and terpene profiles
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Individual dosing and monitoring
This reference provides no starting dose or escalation schedule. If treatment is considered, the preparation, dose, adjustments and monitoring must be individualised. Different products are not directly interchangeable; drops and sprays are not universal dose units.
Routes of administration
The route of administration is part of choosing a specific medicine. Results for one standardised preparation do not automatically establish the effects of another form. Discuss changes with the treating clinician.
Side effects
Adverse effects depend on the active ingredient, preparation and individual circumstances. Drowsiness, dizziness or mental health changes should not be dismissed as an unavoidable price of treatment. Clarify in advance when to contact the team.
Interactions & cautions
Have the complete medication list checked, including non-prescription products. CBD can also cause interactions. Pregnancy, breastfeeding, liver disease and previous mental health difficulties may matter; the specific medicine’s prescribing information is decisive.
Prescription & insurance (Switzerland)
Since August 2022, medical prescribing of cannabis medicines no longer requires an exceptional FOPH permit. This does not establish authorisation for every condition or automatic reimbursement. The preparation, indication and applicable reimbursement rules need separate assessment.
Driving fitness
If a person can demonstrate that THC comes from medication prescribed by a doctor, its presence alone does not establish unfitness to drive (Article 2(2ter) of the Swiss Traffic Rules Ordinance). Actual driving ability remains decisive. A prescription is therefore not blanket permission to drive. Discuss possible effects on attention and reactions with your treating clinician. Do not drive while impaired, and take particular care when starting or changing treatment. Safety-sensitive tasks at work also need an individual assessment.
FAQ
What can be said about effectiveness?
Cannabis studies in fibromyalgia are small and test different preparations. The 2023 review describes limited evidence; the updated 2025 AHRQ assessment also does not justify a universally recommended product profile. Possible changes in pain and quality of life must be read alongside adverse effects and study limitations.
Does a prescription guarantee reimbursement?
No. Prescribing, medicine authorisation and reimbursement are separate questions. Clarify which rules apply to the preparation and indication, including whether prior reimbursement approval is needed.
Is there a universally recommended product profile?
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Does a prescription automatically allow driving?
A prescription alone cannot answer that question. Where medically prescribed use is demonstrated, detecting THC does not by itself establish unfitness to drive. Driving while impaired remains prohibited. Discuss your individual circumstances with your treating clinician.